JPS61194034A - 経鼻投与用粉末状組成物 - Google Patents

経鼻投与用粉末状組成物

Info

Publication number
JPS61194034A
JPS61194034A JP60034581A JP3458185A JPS61194034A JP S61194034 A JPS61194034 A JP S61194034A JP 60034581 A JP60034581 A JP 60034581A JP 3458185 A JP3458185 A JP 3458185A JP S61194034 A JPS61194034 A JP S61194034A
Authority
JP
Japan
Prior art keywords
cellulose
alkyl ether
nasal administration
lower alkyl
powder composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP60034581A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0430926B2 (enExample
Inventor
Kunio Sekine
関根　邦男
Daisuke Araki
大輔 荒木
Yoshiki Suzuki
嘉樹 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Priority to JP60034581A priority Critical patent/JPS61194034A/ja
Priority to EP86301317A priority patent/EP0193372B1/en
Priority to DE8686301317T priority patent/DE3676515D1/de
Publication of JPS61194034A publication Critical patent/JPS61194034A/ja
Priority to MYPI87000102A priority patent/MY102422A/en
Priority to US07/132,447 priority patent/US4985242A/en
Publication of JPH0430926B2 publication Critical patent/JPH0430926B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP60034581A 1985-02-25 1985-02-25 経鼻投与用粉末状組成物 Granted JPS61194034A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP60034581A JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物
EP86301317A EP0193372B1 (en) 1985-02-25 1986-02-24 Intranasally applicable powdery pharmaceutical composition
DE8686301317T DE3676515D1 (de) 1985-02-25 1986-02-24 Intranasal applizierbare pharmazeutische puder.
MYPI87000102A MY102422A (en) 1985-02-25 1987-02-05 Intranasally applicable powdery pharmaceutical composition.
US07/132,447 US4985242A (en) 1985-02-25 1987-12-14 Intranasally applicable powdery pharmaceutical composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60034581A JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物

Publications (2)

Publication Number Publication Date
JPS61194034A true JPS61194034A (ja) 1986-08-28
JPH0430926B2 JPH0430926B2 (enExample) 1992-05-25

Family

ID=12418284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60034581A Granted JPS61194034A (ja) 1985-02-25 1985-02-25 経鼻投与用粉末状組成物

Country Status (5)

Country Link
US (1) US4985242A (enExample)
EP (1) EP0193372B1 (enExample)
JP (1) JPS61194034A (enExample)
DE (1) DE3676515D1 (enExample)
MY (1) MY102422A (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62178524A (ja) * 1986-01-23 1987-08-05 ベ−リングヴエルケ・アクチエンゲゼルシヤフト 鼻内投与用製剤およびその製造法
JPH01132532A (ja) * 1987-10-15 1989-05-25 Syntex Usa Inc 粉末形態ポリプペチド類の経鼻投与
JP2007084508A (ja) * 2005-09-26 2007-04-05 Shiseido Co Ltd 新規血管内皮増殖因子発現阻害剤
JP2008515870A (ja) * 2004-10-11 2008-05-15 ナサリーズ・ピーピーエム・リミテッド 経鼻投与用組成物

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY102411A (en) * 1986-12-23 1992-06-17 Ciba Geigy Ag Nasal solutions
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
NO179479C (no) * 1988-03-11 1996-10-16 Teikoku Seiyaku Kk Fremgangsmåte for fremstilling av et intravaginalt farmasöytisk preparat
US5260270A (en) * 1988-03-30 1993-11-09 The Johns Hopkins University Odorant-binding protein from rat
EP0360340A1 (en) * 1988-09-19 1990-03-28 Akzo N.V. Composition for nasal administration containing a peptide
US5514365A (en) * 1988-10-11 1996-05-07 Schiapparelli Salute S.P.A. Pharmaceutical compositions comprising calcitonin for intranasal administration
IL91856A0 (en) * 1988-10-11 1990-06-10 Schiapparelli Salute Spa Pharmaceutical compositions comprising calcitonin for intranasal administration and a spray unit for the administration of the same
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5567682A (en) * 1988-12-16 1996-10-22 Advanced Peptides And Biotechnology Sciences Method of treating Alzheimer's disease
JP2704546B2 (ja) * 1989-04-04 1998-01-26 光利 太良 Ａｔｌｌ治療用吸入剤
JP2514249B2 (ja) * 1989-05-23 1996-07-10 帝人株式会社 安定化されたカルシトニン類医薬組成物
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
DE69001991T2 (de) * 1989-11-16 1993-09-23 Phidea Spa Fluessige arzneimittel zur nasalen anwendung, die ein polypeptid als wirksubstanz enthalten.
GB9000459D0 (en) * 1990-01-09 1990-03-07 James Michael H Medicaments for treatment of airborne allergies
US5681814A (en) * 1990-06-07 1997-10-28 Genentech, Inc. Formulated IGF-I Composition
ATE113469T1 (de) * 1990-06-21 1994-11-15 Edith Dr Huland Verwendung zytokinhaltiger aerosole und zytokinhaltige aerosole selbst.
US5780012A (en) * 1990-06-21 1998-07-14 Huland; Edith Method for reducing lung afflictions by inhalation of cytokine solutions
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IT1242019B (it) * 1990-11-20 1994-02-02 Ripari Gero Ist Farm Biolog Composizioni farmaceutiche acquose a base di calcitonina, da somministrarsi per via nasale.
JP3179538B2 (ja) * 1990-12-11 2001-06-25 ノバルティス アクチエンゲゼルシャフト 安定なヒトカルシトニンの水性溶液
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5227152A (en) * 1991-04-09 1993-07-13 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5306482A (en) * 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
SG49239A1 (en) * 1991-05-24 1998-05-18 Amylin Pharmaceuticals Inc Amylin and possibly insulin containing composition for the treatment of aneroxia and related states
DE4222647A1 (de) * 1991-07-15 1993-01-21 Sandoz Ag Peptid-zubereitungen
WO1993001826A1 (en) * 1991-07-19 1993-02-04 East Carolina University Method of treating asthma
US5571788A (en) * 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
US5192743A (en) * 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
CA2115065C (en) * 1992-06-12 2000-10-03 Kiyoyuki Sakon Ultrafine particle powder for inhalation and method for production thereof
KR100208979B1 (ko) * 1992-06-12 1999-07-15 야스이 쇼사꾸 기도내 투여용 제제
DK17093D0 (da) * 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1101701C (zh) * 1993-06-29 2003-02-19 凡林有限公司 由鼻给药的去氨加压素组合物及其制备方法和用途
ATE416755T1 (de) 1994-03-07 2008-12-15 Nektar Therapeutics Verfahren und zusammensetzung für die pulmonale darreichung von insulin
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
ES2243994T5 (es) 1996-04-19 2009-10-29 Grifols Inc. Procedimiento para la inactivacion virica de proteinas de la sangre liofilizadas.
US7153845B2 (en) * 1998-08-25 2006-12-26 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US8765177B2 (en) * 1997-09-12 2014-07-01 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets
US6190699B1 (en) * 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
DE19826628C1 (de) * 1998-06-17 2000-07-20 Werner Kern Intranasale Verwendung von Insulin bei Hirnleistungsstörungen
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
DK1398038T4 (da) * 2000-02-08 2011-03-28 Allergan Inc Lægemidler med botulinustoxin
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
PT1372611E (pt) * 2001-03-26 2006-08-31 Novartis Ag Composicao farmaceutica compreendendo uma estaurosporina francamente soluvel em agua, um tensioactivo et um polimero soluvel em agua
AU2002346424A1 (en) * 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
US20040005999A1 (en) * 2002-03-07 2004-01-08 Andreasen Kasper Huus Polyamino acid-based particle insulin preparation
WO2004084859A2 (en) 2003-03-21 2004-10-07 Nastech Pharmaceutical Company Inc. Nasal calcitonin formulations containing chlorobutanol
US20050058673A1 (en) * 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
US20070172517A1 (en) * 2003-09-17 2007-07-26 Ben-Sasson Shmuel A Compositions capable of facilitation penetration across a biological barrier
US20060051384A1 (en) * 2004-09-07 2006-03-09 3M Innovative Properties Company Antiseptic compositions and methods of use
US9028852B2 (en) * 2004-09-07 2015-05-12 3M Innovative Properties Company Cationic antiseptic compositions and methods of use
US8198326B2 (en) * 2004-09-07 2012-06-12 3M Innovative Properties Company Phenolic antiseptic compositions and methods of use
GB0422582D0 (en) * 2004-10-11 2004-11-10 Nasaleze Patents Ltd Pharmaceutical compositions
US7396936B1 (en) 2004-11-09 2008-07-08 Kemia, Inc. Modulators of calcitonin and amylin receptor activity
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
BRPI0608691A2 (pt) * 2005-03-10 2010-12-07 3M Innovative Properties Company composição antimicrobiana, e, métodos para matar ou inativar microorganismos em tecido da mucosa de um mamìfero, para tratar uma lesão ou ferimento infectado, para descolonização de microorganismos, para proporcionar eficácia antimicrobiana residual sobre uma superfìcie e para tratar uma condição
BRPI0608690B8 (pt) * 2005-03-10 2021-05-25 3M Innovative Properties Co uso de uma composição antimicrobiana
US7580130B2 (en) * 2005-03-23 2009-08-25 Datacolor Holding Ag Method for designing a colorimeter having integral illuminant-weighted CIE color-matching filters
EP2091324B1 (en) 2006-10-27 2016-12-28 3M Innovative Properties Company Antimicrobial compositions
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
MX2016002705A (es) * 2013-09-03 2016-09-06 G2B Pharma Inc Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5989619A (ja) * 1982-10-05 1984-05-23 サンド・アクチエンゲゼルシヤフト カルシトニン組成物およびその用途
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
CA986441A (en) * 1971-10-22 1976-03-30 Aslam Khwaja Enzyme treatment
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPS58189118A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 経鼻投与製剤
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
AU572815B2 (en) * 1982-12-29 1988-05-19 Armour Pharmaceutical Company Pharmaceutical calcitonin compositions for intranasal application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5989619A (ja) * 1982-10-05 1984-05-23 サンド・アクチエンゲゼルシヤフト カルシトニン組成物およびその用途
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62178524A (ja) * 1986-01-23 1987-08-05 ベ−リングヴエルケ・アクチエンゲゼルシヤフト 鼻内投与用製剤およびその製造法
JPH01132532A (ja) * 1987-10-15 1989-05-25 Syntex Usa Inc 粉末形態ポリプペチド類の経鼻投与
JP2008515870A (ja) * 2004-10-11 2008-05-15 ナサリーズ・ピーピーエム・リミテッド 経鼻投与用組成物
JP2007084508A (ja) * 2005-09-26 2007-04-05 Shiseido Co Ltd 新規血管内皮増殖因子発現阻害剤

Also Published As

Publication number Publication date
JPH0430926B2 (enExample) 1992-05-25
MY102422A (en) 1992-06-30
EP0193372A3 (en) 1987-07-01
US4985242A (en) 1991-01-15
EP0193372B1 (en) 1990-12-27
DE3676515D1 (de) 1991-02-07
EP0193372A2 (en) 1986-09-03

Similar Documents

Publication Publication Date Title
JPS61194034A (ja) 経鼻投与用粉末状組成物
TWI292716B (en) Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US20030059376A1 (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
WO2000074736A9 (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
JPH05508616A (ja) 治療用エアロゾル剤
JP2008163033A (ja) エアゾール化医薬の肺への送達
JPH05963A (ja) ポリペプチド類組成物
JPH06510046A (ja) 治療薬の舌下または頬投与のための組成物及び方法
NZ535008A (en) Polymer-based compositions for sustained release
JPH07165613A (ja) 経鼻吸収薬物用キャリヤおよび生理活性ペプチド組成物
JPS632932A (ja) 経鼻投与用粉末状組成物
JPS6242888B2 (enExample)
EP0140255A2 (en) Sustained-release injections
GB2193891A (en) Nasal pharmaceutical compositions containing octreotide
JP2003533472A (ja) 吸入用インスリン製剤
JP2505430B2 (ja) 塩基性アミノ酸を含有する経鼻投与用粉末状組成物
CA2291765A1 (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
JP3263598B2 (ja) 経鼻吸収用生理活性ペプチド組成物
JPS58189118A (ja) 経鼻投与製剤
JP2987883B2 (ja) Ｆｒ１１５２２４物質の非経口投与用製剤
JP3555961B2 (ja) 安定なペプチド医薬組成物
JPH0480008B2 (enExample)
JPWO2004078211A1 (ja) 粉末経鼻投与製剤
JP3608802B2 (ja) 安定なカルシトニン医薬組成物及びその製造法
CN102905717B (zh) 经鼻投与用组合物及其制造方法

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term